| Literature DB >> 35924913 |
Nicholas M Smith1,2, Katie Rose Boissonneault1,2, Liang Chen3,4, Vidmantas Petraitis5, Ruta Petraitiene5, Xun Tao6, Jieqiang Zhou6, Yinzhi Lang6, Povilas Kavaliauskas5, Zackery P Bulman7, Patricia N Holden1,2, Raymond Cha1,2, Jürgen B Bulitta6, Barry N Kreiswirth3, Thomas J Walsh4,8,9,10, Brian T Tsuji1,2.
Abstract
Metallo-β-lactamase (MBL)-producing Gram-negative bacteria cause infections associated with high rates of morbidity and mortality. Currently, a leading regimen to treat infections caused by MBL-producing bacteria is aztreonam combined with ceftazidime-avibactam. The purpose of the present study was to evaluate and rationally optimize the combination of aztreonam and ceftazidime-avibactam with and without polymyxin B against a clinical Klebsiella pneumoniae isolate producing NDM-1 and CTX-M by use of the hollow fiber infection model (HFIM). A novel de-escalation approach to polymyxin B dosing was also explored, whereby a standard 0-h loading dose was followed by maintenance doses that were 50% of the typical clinical regimen. In the HFIM, the addition of polymyxin B to aztreonam plus ceftazidime-avibactam significantly improved bacterial killing, leading to eradication, including for the novel de-escalation dosing strategy. Serial samples from the growth control and monotherapies were explored in a Galleria mellonella virulence model to assess virulence changes. Weibull regression showed that low-level ceftazidime resistance and treatment with monotherapy resulted in increased G. mellonella mortality (P < 0.05). A neutropenic rabbit pneumonia model demonstrated that aztreonam plus ceftazidime-avibactam with or without polymyxin B resulted in similar bacterial killing, and these combination therapies were statistically significantly better than monotherapies (P < 0.05). However, only the polymyxin B-containing combination therapy produced a statistically significant decrease in lung weights (P < 0.05), indicating a decreased inflammatory process. Altogether, adding polymyxin B to the combination of aztreonam plus ceftazidime-avibactam for NDM- and CTX-M-producing K. pneumoniae improved bacterial killing effects, reduced lung inflammation, suppressed resistance amplification, and limited virulence changes.Entities:
Keywords: CTX-M; Enterobacterales; Klebsiella pneumoniae; New Delhi metallo-beta-lactamase; aztreonam; ceftazidime-avibactam; metallo-beta-lactamase; pharmacodynamics; pharmacokinetics; polymyxin B
Mesh:
Substances:
Year: 2022 PMID: 35924913 PMCID: PMC9487485 DOI: 10.1128/aac.00527-22
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.938